Collaboration and License Agreements - Additional Information (Details)	1 Months Ended	3 Months Ended		6 Months Ended
	Mar. 31, 2020 USD ($) Target	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Collaboration And License Agreements [Line Items]
Collaboration and license revenue		$ 4,056,000	$ 2,848,000	$ 7,077,000	$ 4,875,000
Incurred costs		19,302,000	$ 13,527,000	38,486,000	23,472,000
Deferred revenue, current portion		8,170,000		8,170,000		$ 11,410,000
Long-term deferred revenue		$ 0		$ 0		$ 1,497,000
Maximum | Novartis Agreement
Collaboration And License Agreements [Line Items]
Ownership Interest		10.00%		10.00%
Minimum | Novartis Agreement
Collaboration And License Agreements [Line Items]
Ownership Interest	10.00%
Novartis
Collaboration And License Agreements [Line Items]
License agreement date	Mar. 31, 2020
Upfront payment received	$ 20,000,000.0
Upfront payment receivable	$ 20,000,000.0
Negotiation period				180 days
Expects research term	3 years
Collaboration and license revenue				$ 7,100,000	4,700,000
Incurred costs				2,300,000	$ 700,000
Deferred revenue, current portion		$ 8,200,000		8,200,000
Long-term deferred revenue		$ 0		$ 0
Novartis | Maximum
Collaboration And License Agreements [Line Items]
Number of targets identified | Target	3
Novartis | Research Funding
Collaboration And License Agreements [Line Items]
Upfront payment received	$ 10,000,000.0
Upfront payment receivable	$ 10,000,000.0